BeiGene (688235.SH) net profit of 3.271 billion yuan in the first half of the year increased 627.1% year-on-year

According to Zhitong Finance App News, BeiGene (688235.SH) announced that the company's product revenue for the 2026 semi-year was 21.797 billion yuan, up 25.6% year on year; the company's total revenue for the first half year of 2026 was 22.220 billion yuan, up 26.8% year on year; net profit attributable to parent company owners for the first half year of 2026 was 3.271 billion yuan, up 627.1% year on year. After excluding the impact of non-cash items such as share payments, depreciation and amortization expenses, the adjusted operating profit for the 2026 semi-year was 6.508 billion yuan, up 101.9% year on year; adjusted net profit for the 2026 semi-year was 5.863 billion yuan, up 127.0% year on year. At the end of the reporting period, the company's total assets were 62,499 billion yuan, up 9.1% from the beginning of the period; owners' equity attributable to the parent company was 35.427 billion yuan, an increase of 15.6% over the beginning of the period.

In the first half of 2026, product revenue was 21.797 billion yuan, and product revenue for the same period last year was 17.360 billion yuan. The increase in product revenue was mainly due to sales growth of Baiyuze® (zebutinib), products authorized by Amgen, and Baizean® (tirelizumab).

In the first half of 2026, Baiyuze®'s global sales totaled 16.127 billion yuan, an increase of 28.7% over the previous year. Among them, US sales totaled 11.390 billion yuan, an increase of 27.2% over the previous year. In the first half of 2026, Baizeon®'s global sales totaled 2,984 billion yuan, an increase of 12.9% over the previous year. In the first half of 2026, sales of Amgen's authorized products were 2,065 billion yuan, an increase of 19.6% over the previous year.